¥È¥Ã¥×
|
²ñ¼Ò³µÍ×
|
¶È̳ÈÏ°Ï
|
ÆÈÆäÊËÝÌõÉô
|
ÉʼÁÊݾÚ
|
À®¸ùÎã
|
ºÎÍѾðÊó
|
¤ªÌ䤤¹ç¤ï¤»
¶È̳ÈÏ°Ï
 
´ðÁðå³Ø¤ÈÎ×¾² ¾Ü¤·¤¯

À¸Íý³Ø¡¢ÉÂÍý³Ø¡¢À¸Êª²½³Ø¡¢Ê¬»ÒÀ¸Êª³Ø¡¢¥Ð¥¤¥ª°å³Ø¹©Äø¡¢½Û´Ä´ïÆâ²Ê¡¢¸ÆµÛ´ïÆâ²Ê¡¢Ç¾³°²Ê¡¢¿À·Ð³°²Ê...

 
Ìô³Ø»ñÎÁ ¾Ü¤·¤¯

ÌôÍý³Ø¡¢ÆÇÍý³Ø¡¢ÌôÉʲ½³Ø¡¢ÌôÉÊʬÀϳء¢ÌôºÞ³Ø¡¢À½ºÞ½èÊý¤ª¤è¤Óµ»½Ñ¡¢¸¶ÎÁ¡¦ÊäºÞ¤ÎͳÍ褪¤è¤ÓÉʼÁ´ð...

 
°åÎÅ´ï³£¤ª¤è¤ÓÀ½ÉÊ ¾Ü¤·¤¯

IEC¡Ê¹ñºÝÅŵ¤É¸½à²ñµÄ¡ËÊó¹ð¡¢¥ì¥ó¥È¥²¥óµ¡´ï¡¢Ä¶²»Çȵ¡´ï¡¢MRI¡¢CT¡¢¸ÆµÛµ¡¡¢·ì±Õ¾ô²½Íѵ¡...

 
¹ñºÝ²ñµÄƱ»þÄÌÌõ ¾Ü¤·¤¯

¹ñºÝ²ñµÄ¡¢¸¦µæƤÏÀ²ñ¡¢Ç¯²ñ²ñµÄ¤Î¸½¾ìÄÌÌõ¡¢Æ±»þÄÌÌõ¡¢±óµ÷Î¥²ñµÄËÝÌõ¡¢±ÇÁü»ñÎÁ¡¢Âç²ñµÄÆüÄøËÝÌõ¡¢...

À®¸ùÎã
SFDA
WHO(World Health
WHO(World Health
Novartis Pharma
Beijing Municipa
Bayer
Healthcare
Chinese Medical
Nycomed Pharma
 
 
·­Òë´Ê»ãÏÂÔØ
ÁÙ´²´Ê»ã
¡¡¡¤ ¶ù¿Æ ¡¡¡¤ ·ÅÉä¿Æ ¡¡¡¤ ¸¾²ú¿Æ
¡¡¡¤ ÄÚ¿Æ ¡¡¡¤ Ƥ·ô¿Æ ¡¡¡¤ Éñ¾­¿Æ
¡¡¡¤ Íâ¿Æ ¡¡¡¤ Îå¹Ù¿Æ ¡¡¡¤ ÑÛ¿Æ
¡¡¡¤ Õï¶Ïѧ ¡¡¡¤ Ö×Áö¿Æ ¡¡¡¤ Ò½Ôº¡¢¿ÆÊÒºÍҽʦÃû
¡¡¡¤ ¼²²¡Ãû´Ê»ã
Ö×Áö¿Æ
Englishi
ÖÐÎÄ
Englishi
ÖÐÎÄ
adenocarcinoma
ÏÙ¹ÜÉÏƤ£¬ÏÙ°©
malignant meningioma
ÄÔĤ£¬¶ñÐÔÄÔĤÁö
adrenal cortical carcinoma
ÉöÉÏÏÙƤÖÊ£¬ÉöÉÏÏÙƤÖÊ°©
malignant mesothelioma
¼äƤ£¬¶ñÐÔ¼äƤÁö
Alpha-Iantitrypsin deficiency
a-¿¹¼××´ÏÙËØȱ·¦Ö¢
malignant mixed tumor
ÍÙÒºÏÙ£¬¶ñÐÔ»ìºÏÁö
American Joint Committee on Cancer Staging; AJCC
ÃÀ¹ú°©Ö¢·ÖÆÚÁªºÏίԱ»á
malignant pheochromocytoma
ÉöÉÏÏÙËèÖÊ£¬¶ñÐÔÊȸõϸ°ûÁö
angiosarcoma
Ѫ¹ÜÄÚƤ£¬Ñª¹ÜÈâÁö
malignant phyllodes tumor
Èé·¿£¬¶ñÐÔҶ״Áö
basal cell carcinoma
»ùµ×ϸ°û£¬»ùµ×ϸ°û°©
malignant teratoma
¶ñÐÔ»ûÌ¥Áö
breast carcinoma
ÈéÏÙ°©
melanoma
°©Ö¢£¬ºÚËØÁö
carcinoembryonic antigen; CEA
°©Åß¿¹Ô­
mesothelioma
¼äƤÁö
carcinoma
¶ñÐÔÉÏƤÖ×Áö
Microinvasive carcinoma
΢ÇÖÏ®°©
Carcinoma in situ
ԭλ°©
mild dysplasia
Çá¶ÈÒìÉú
catecholamine
¶ù²è·Ó°·
moderate dysplasia
ÖжÈÒìÉú
cerebroma
ÄÔÁö
moderately differentiated
Öжȷֻ¯
chondrosarcoma
Èí¹Ç£¬Èí¹ÇÈâÁö
multiple myeIoma
¶à·¢ÐÔ¹ÇËèÁö
choriocarcinoma
Ì¥ÅÌÉÏƤ£¬ÈÞëĤ°©
myeloma
½¬Ï¸°û£¬¹ÇËèÁö
colon cancer
½á³¦°©
neuroblastoma
Éñ¾­½Úϸ°û£¬Éñ¾­Ä¸Ï¸°ûÁö
Cysticfibrosis
ÄÒÐÔÏËά±äÐÔ
neuroblastoma
Éñ¾­Ä¸Ï¸°ûÁö
direct extension
Ö±½ÓÂûÑÓ
neuroblastoma
Éñ¾­Ä¸Ï¸°ûÁö
dysgerminoma
¶ñÐÔÅßÌ¥Áö
neuron-specific enolase; NSE
Éñ¾­ÌØÒìÐÔÏ©´¼
Dysplasia
񓃜
oma
Á¼ÐÔÖ×Áö
Familialhypercholesterolemia
¼Ò×åÐÔµ¨¹Ì´¼¹ý¶àÖ¢
osteosarcoma
Ó²¹Ç£¬¹ÇÈâÁö
Fanconi sanemia Fanconi's
ƶѪ֢
ova-rian
Âѳ²°©
fibrosarcoma
ÏËά×éÖ¯£¬ÏËάÈâÁö
poorly differentiated
·Ö»¯²»Á¼
glioma
Éñ¾­½ºÏ¸°û£¬Éñ¾­½ºÏ¸°ûÁö
prostate-specific antigen; PSA
Ç°ÁÐÏÙÌØÒìÐÔ¿¹Ô­
hematogenous metastasis
ѪÐÐתÒÆ
prostatic acid phosphatase; PAP
Ç°ÁÐÏÙËáÐÔÁ×Ëá
HemophiIia
ѪÓѲ¡
prostatic csarcinoma
Ç°ÁÐÏÙ°©
hepatocellular carcinoma; hepatoma
¸Îϸ°û£¬¸Îϸ°û°©
Purine nucleoside phosphorylase deficiency
æÎÒ÷ºË¿àËáÁ×ËáËáȱ·¦Ö¢
hepatoma ;liver cancer
¸Î°©
renal cell carcinoma
ÉöÔàÉÏƤ£¬Éöϸ°û°©
histopathological grading
×éÖ¯²¡Àí·Ö»¯
renaleelI
Éöϸ°û°©
human chorionic gonadotropin; HCG
ÈËÀàÈÞëĤ´ÙÐÔÏÙËØ
rhabdomyosarcoma
ºáÎƼ¡£¬ºáÎƼ¡ÈâÁö
Hunter'ssyndrome
ºàÌØÊÏ×ÛºÏÖ¢
sarcoma
¶ñÐÔ¼äÒ¶Ö×Áö
immature teratoma
È«ÄÜϸ°û£¬Î´³ÉÊì»ûÌ¥Áö
SCID
ÑÏÖظ´ºÏÃâÒßȱʧ֢
Invasive carcinoma
ÇÖÏ®°©
seminoma
Éúֳϸ°û£¬¾«Ï¸°ûÁö
leiomyosarcoma
ƽ»¬¼¡£¬Æ½»¬¼¡ÈâÁö
severe dysplasia
ÖضÈÒìÉú
leukemia
ÔìѪϸ°û£¬°×Ѫ²¡
squamous cell carcinoma
ÁÛ×´ÉÏƤ£¬ÁÛ״ϸ°û°©
leukemia
×Ôϸ°ûÁö
stage
ÆÚ±ð
liposarcoma
Ö¬·¾×éÖ¯£¬Ö¬·¾ÈâÁö
synovial sarcoma
»¬Ä¤£¬»¬Ä¤ÈâÁö
lung cancer
·Î°©
thymic carcinoma
ÐØÏÙÉÏƤ£¬ÐØÏÙ°©
lymphangiosarcoma
Áܰ͹ÜÄÚƤ£¬Áܰ͹ÜÈâÁö
transitional cell carcinoma
ÃÚÄòµÀÉÏƤ£¬¹ý¶Éϸ°û°©
lymphatic metastasis
ÁÜ°ÍתÒÆ
tumor marker
ÁÙ´²¼ìÑ飬º¬Ö×Áö±ê¼Ç
lymphoma
ÀàÁÜ°Í×éÖ¯£¬ÁÜ°ÍÁö
undifferentiated
δ·Ö»¯
lymphoma
ÁÜ°ÍÈâÁö
well differentiated
·Ö»¯Á¼ºÃ
malignant melanoma
Éñ¾­ÍâÅ߲㣬¶ñÐÔºÚÉ«ËØÁö
¼Ò×åÐÔÆ¢ÐÔƶѪ
Gaucher's²¡
 
©

2004-2019Ë̵þ°ÉÎÓ°åÌôËÝÌõ¥»¥ó¥¿¡¼